Advertisement
Gynecologic Oncology
Advanced searchSave search
A Society of Gynecologic Oncology Evidence-based Review (and Recommendations)| Volume 160, ISSUE 1, P322-332, January 2021

Download started.

Ok

Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies

Published:November 04, 2020DOI:https://doi.org/10.1016/j.ygyno.2020.10.017
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies
Previous ArticleDirect oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement
Next ArticleThe current landscape of molecular profiling in the treatment of epithelial ovarian cancer

      Highlights

      • •
        USC is a distinct type of uterine cancer with poor prognosis, responsible for up to 40% of uterine cancer-related deaths.
      • •
        Molecular features of USC include TP53 mutation, cell cycle changes, ERBB2 amplification, and changes in PI3K signaling.
      • •
        Recent advances in USC therapy include addition of trastuzumab to chemotherapy in ERBB2-amplified cancers.
      • •
        The combination of pembrolizumab and lenvatinib has also demonstrated substantial activity in USC.
      • •
        Novel therapies targeting HER2 and PI3K signaling or the DNA damage response pathway are being developed in USC.

      Abstract

      Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer. Multimodality treatment with surgery, radiotherapy, and chemotherapy is commonly used, given its propensity for extrauterine spread, distant recurrences, and poor prognosis. However, the use of molecularly-based therapy is expanding. Here, we review key molecular features of USC, discuss current management, and assess the landscape of novel therapies and combinations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2020.
        CA Cancer J. Clin. 2020; 70: 7-30https://doi.org/10.3322/caac.21590
        View in Article
        • McGunigal M.
        • Liu J.
        • Kalir T.
        • Chadha M.
        • Gupta V.
        Survival differences among uterine papillary serous, clear cell and grade 3 endometrioid adenocarcinoma endometrial cancers: a national cancer database analysis.
        in: Int. J. Gynecol. Cancer. Lippincott Williams and Wilkins, 2017: 85-92https://doi.org/10.1097/IGC.0000000000000844
        View in Article
        • Kurman R.
        • Carcangiu M.L.
        • Herrington C.S.
        • Young R.H.
        WHO Classification of Tumours of Female Reproductive Organs.
        Lyon IARC Press, 2014
        View in Article
        • Zheng W.
        • Xiang L.
        • Fadare O.
        • Kong B.
        A proposed model for endometrial serous carcinogenesis.
        Am. J. Surg. Pathol. 2011; 35: 1-14https://doi.org/10.1097/PAS.0b013e318202772e
        View in Article
        • Tolcher M.C.
        • Swisher E.M.
        • Medeiros F.
        • Lima J.F.
        • Hilderbrand J.L.
        • Donovan J.L.
        • Garcia R.L.
        • Cliby W.A.
        • Dowdy S.C.
        Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma.
        Int. J. Gynecol. Pathol. 2015; 34: 57-64https://doi.org/10.1097/PGP.0000000000000109
        View in Article
        • Kuhn E.
        • Wu R.C.
        • Guan B.
        • Wu G.
        • Zhang J.
        • Wang Y.
        • Song L.
        • Yuan X.
        • Wei L.
        • Roden R.B.S.
        • Kuo K.T.
        • Nakayama K.
        • Clarke B.
        • Shaw P.
        • Olvera N.
        • Kurman R.J.
        • Levine D.A.
        • Wang T.L.
        • Shih I.M.
        Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
        J. Natl. Cancer Inst. 2012; 104: 1503-1513https://doi.org/10.1093/jnci/djs345
        View in Article
        • Slomovitz B.M.
        • Burke T.W.
        • Eifel P.J.
        • Ramondetta L.M.
        • Silva E.G.
        • Jhingran A.
        • Oh J.C.
        • Atkinson E.N.
        • Broaddus R.R.
        • Gershenson D.M.
        • Lu K.H.
        Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.
        Gynecol. Oncol. 2003; 91: 463-469https://doi.org/10.1016/j.ygyno.2003.08.018
        View in Article
        • Liang S.X.
        • Pearl M.
        • Liang S.
        • Xiang L.
        • Jia L.
        • Yang B.
        • Fadare O.
        • Schwartz P.E.
        • Chambers S.K.
        • Kong B.
        • Zheng W.
        Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger.
        Int. J. Cancer. 2011; 128: 763-770https://doi.org/10.1002/ijc.25395
        View in Article
        • Shu C.A.
        • Pike M.C.
        • Jotwani A.R.
        • Friebel T.M.
        • Soslow R.A.
        • Levine D.A.
        • Nathanson K.L.
        • Konner J.A.
        • Arnold A.G.
        • Bogomolniy F.
        • Dao F.
        • Olvera N.
        • Bancroft E.K.
        • Goldfrank D.J.
        • Stadler Z.K.
        • Robson M.E.
        • Brown C.L.
        • Leitao M.M.
        • Abu-Rustum N.R.
        • Aghajanian C.A.
        • Blum J.L.
        • Neuhausen S.L.
        • Garber J.E.
        • Daly M.B.
        • Isaacs C.
        • Eeles R.A.
        • Ganz P.A.
        • Barakat R.R.
        • Offit K.
        • Domchek S.M.
        • Rebbeck T.R.
        • Kauff N.D.
        Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA Mutations.
        JAMA Oncol. 2016; 2: 1434-1440https://doi.org/10.1001/jamaoncol.2016.1820
        View in Article
        • Gerber D.
        • Dao F.
        • Olvera N.
        • Piccola N.
        • Levine D.A.
        Frequency of BRCA1 and BRCA2 germline mutations in uterine serous carcinomas and uterine carcinosarcomas.
        J. Clin. Oncol. 2018; 36: e13521https://doi.org/10.1200/JCO.2018.36.15_suppl.e13521
        View in Article
        • Zhao S.
        • Choi M.
        • Overton J.D.
        • Bellone S.
        • Roque D.M.
        • Cocco E.
        • Guzzo F.
        • English D.P.
        • Varughese J.
        • Gasparrini S.
        • Bortolomai I.
        • Buza N.
        • Hui P.
        • Abu-Khalaf M.
        • Ravaggi A.
        • Bignotti E.
        • Bandiera E.
        • Romani C.
        • Todeschini P.
        • Tassi R.
        • Zanotti L.
        • Carrara L.
        • Pecorelli S.
        • Silasi D.A.
        • Ratner E.
        • Azodi M.
        • Schwartz P.E.
        • Rutherford T.J.
        • Stiegler A.L.
        • Mane S.
        • Boggon T.J.
        • Schlessinger J.
        • Lifton R.P.
        • Santin A.D.
        Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
        Proc. Natl. Acad. Sci. U. S. A. 2013; 110: 2916-2921https://doi.org/10.1073/pnas.1222577110
        View in Article
        • Getz G.
        • Gabriel S.B.
        • Cibulskis K.
        • Lander E.
        • Sivachenko A.
        • Sougnez C.
        • Lawrence M.
        • Kandoth C.
        • Dooling D.
        • Fulton R.
        • Fulton L.
        • Kalicki-Veizer J.
        • McLellan M.D.
        • O’Laughlin M.
        • Schmidt H.
        • Wilson R.K.
        • Ye K.
        • Li D.
        • Ally A.
        • Balasundaram M.
        • Birol I.
        • Butterfield Y.S.N.
        • Carlsen R.
        • Carter C.
        • Chu A.
        • Chuah E.
        • Chun H.J.E.
        • Dhalla N.
        • Guin R.
        • Hirst C.
        • Holt R.A.
        • Jones S.J.M.
        • Lee D.
        • Li H.I.
        • Marra M.A.
        • Mayo M.
        • Moore R.A.
        • Mungall A.J.
        • Plettner P.
        • Schein J.E.
        • Sipahimalani P.
        • Tam A.
        • Varhol R.J.
        • Robertson A. Gordon
        • Cherniack A.D.
        • Pashtan I.
        • Saksena G.
        • Onofrio R.C.
        • Schumacher S.E.
        • Tabak B.
        • Carter S.L.
        • Hernandez B.
        • Gentry J.
        • Salvesen H.B.
        • Ardlie K.
        • Winckler W.
        • Beroukhim R.
        • Meyerson M.
        • Hadjipanayis A.
        • Lee S.
        • Mahadeshwar H.S.
        • Park P.
        • Protopopov A.
        • Ren X.
        • Seth S.
        • Song X.
        • Tang J.
        • Xi R.
        • Yang L.
        • Dong Z.
        • Kucherlapati R.
        • Chin L.
        • Zhang J.
        • Auman J. Todd
        • Balu S.
        • Bodenheimer T.
        • Buda E.
        • Hayes D. Neil
        • Hoyle A.P.
        • Jefferys S.R.
        • Jones C.D.
        • Meng S.
        • Mieczkowski P.A.
        • Mose L.E.
        • Parker J.S.
        • Perou C.M.
        • Roach J.
        • Yan S.
        • Simons J.V.
        • Soloway M.G.
        • Tan D.
        • Topal M.D.
        • Waring S.
        • Wu J.
        • Hoadley K.A.
        • Baylin S.B.
        • Bootwalla M.S.
        • Lai P.H.
        • Triche T.J.
        • Van Den Berg D.J.
        • Weisenberger D.J.
        • Laird P.W.
        • Shen H.
        • Cho J.
        • Dicara D.
        • Frazer S.
        • Heiman D.
        • Jing R.
        • Lin P.
        • Mallard W.
        • Stojanov P.
        • Voet D.
        • Zhang H.
        • Zou L.
        • Noble M.
        • Reynolds S.M.
        • Shmulevich I.
        • Aksoy B. Arman
        • Antipin Y.
        • Ciriello G.
        • Dresdner G.
        • Gao J.
        • Gross B.
        • Jacobsen A.
        • Ladanyi M.
        • Reva B.
        • Sander C.
        • Sinha R.
        • Sumer S. Onur
        • Taylor B.S.
        • Cerami E.
        • Weinhold N.
        • Schultz N.
        • Shen R.
        • Benz S.
        • Goldstein T.
        • Haussler D.
        • Ng S.
        • Szeto C.
        • Stuart J.
        • Benz C.C.
        • Yau C.
        • Zhang W.
        • Annala M.
        • Broom B.M.
        • Casasent T.D.
        • Ju Z.
        • Liang H.
        • Liu G.
        • Lu Y.
        • Unruh A.K.
        • Wakefield C.
        • Weinstein J.N.
        • Zhang N.
        • Liu Y.
        • Broaddus R.
        • Akbani R.
        • Mills G.B.
        • Adams C.
        • Barr T.
        • Black A.D.
        • Bowen J.
        • Deardurff J.
        • Frick J.
        • Gastier-Foster J.M.
        • Grossman T.
        • Harper H.A.
        • Hart-Kothari M.
        • Helsel C.
        • Hobensack A.
        • Kuck H.
        • Kneile K.
        • Leraas K.M.
        • Lichtenberg T.M.
        • McAllister C.
        • Pyatt R.E.
        • Ramirez N.C.
        • Tabler T.R.
        • Vanhoose N.
        • White P.
        • Wise L.
        • Zmuda E.
        • Barnabas N.
        • Berry-Green C.
        • Blanc V.
        • Boice L.
        • Button M.
        • Farkas A.
        • Green A.
        • MacKenzie J.
        • Nicholson D.
        • Kalloger S.E.
        • Gilks C. Blake
        • Karlan B.Y.
        • Lester J.
        • Orsulic S.
        • Borowsky M.
        • Cadungog M.
        • Czerwinski C.
        • Huelsenbeck-Dill L.
        • Iacocca M.
        • Petrelli N.
        • Rabeno B.
        • Witkin G.
        • Nemirovich-Danchenko E.
        • Potapova O.
        • Rotin D.
        • Berchuck A.
        • Birrer M.
        • Disaia P.
        • Monovich L.
        • Curley E.
        • Gardner J.
        • Mallery D.
        • Penny R.
        • Dowdy S.C.
        • Winterhoff B.
        • Dao L.
        • Gostout B.
        • Meuter A.
        • Teoman A.
        • Dao F.
        • Olvera N.
        • Bogomolniy F.
        • Garg K.
        • Soslow R.A.
        • Abramov M.
        • Bartlett J.M.S.
        • Kodeeswaran S.
        • Parfitt J.
        • Moiseenko F.
        • Clarke B.A.
        • Goodman M.T.
        • Carney M.E.
        • Matsuno R.K.
        • Fisher J.
        • Huang M.
        • Rathmell W. Kimryn
        • Thorne L.
        • Van Le L.
        • Dhir R.
        • Edwards R.
        • Elishaev E.
        • Zorn K.
        • Goodfellow P.J.
        • Mutch D.
        • Kahn A.B.
        • Bell D.W.
        • Pollock P.M.
        • Wang C.
        • Wheeler D.
        • Shinbrot E.
        • Robertson A. Gordon
        • Ding L.
        • Gilks C. Blake
        • Mardis E.R.
        • Ayala B.
        • Chu A.L.
        • Jensen M.A.
        • Kothiyal P.
        • Pihl T.D.
        • Pontius J.
        • Pot D.A.
        • Snyder E.E.
        • Srinivasan D.
        • Shaw K.R. Mills
        • Sheth M.
        • Davidsen T.
        • Eley G.
        • Ferguson M.L.
        • Yang L.
        • Guyer M.S.
        • Ozenberger B.A.
        • Sofia H.J.
        • Robertson A. Gordon
        • Levine D.A.
        Integrated genomic characterization of endometrial carcinoma.
        Nature. 2013; https://doi.org/10.1038/nature12113
        View in Article
        • Le Gallo M.
        • O’hara A.J.
        • Rudd M.L.
        • Urick M.E.
        • Hansen N.F.
        • O’neil N.J.
        • Price J.C.
        • Zhang S.
        • England B.M.
        • Godwin A.K.
        • Sgroi D.C.
        • Hieter P.
        • Mullikin J.C.
        • Merino M.J.
        • Bell D.W.
        Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program.
        Nat. Genet. 2012; 44https://doi.org/10.1038/ng.2455
        View in Article
        • Schultheis A.M.
        • Martelotto L.G.
        • De Filippo M.R.
        • Piscuglio S.
        • Ng C.K.Y.
        • Hussein Y.R.
        • Reis-Filho J.S.
        • Soslow R.A.
        • Weigelt B.
        TP53 mutational spectrum in endometrioid and serous endometrial cancers.
        Int. J. Gynecol. Pathol. 2016; https://doi.org/10.1097/PGP.0000000000000243
        View in Article
        • Santin A.D.
        • Bellone S.
        • Van Stedum S.
        • Bushen W.
        • De Las Casas L.E.
        • Korourian S.
        • Tian E.
        • Roman J.J.
        • Burnett A.
        • Pecorelli S.
        Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
        Gynecol. Oncol. 2005; 98: 24-30https://doi.org/10.1016/j.ygyno.2005.03.041
        View in Article
        • Togami S.
        • Sasajima Y.
        • Oi T.
        • Ishikawa M.
        • Onda T.
        • Ikeda S.I.
        • Kato T.
        • Tsuda H.
        • Kasamatsu T.
        Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma.
        Cancer Sci. 2012; 103: 926-932https://doi.org/10.1111/j.1349-7006.2012.02240.x
        View in Article
        • Carvajal-Hausdorf D.E.
        • Schalper K.A.
        • Bai Y.
        • Black J.
        • Santin A.D.
        • Rimm D.L.
        Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
        Gynecol. Oncol. 2017; 145: 154-158https://doi.org/10.1016/j.ygyno.2017.02.002
        View in Article
        • Buza N.
        • English D.P.
        • Santin A.D.
        • Hui P.
        Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.
        Mod. Pathol. 2013; 26: 1605-1612https://doi.org/10.1038/modpathol.2013.113
        View in Article
        • Erickson B.K.
        • Najjar O.
        • Damast S.
        • Blakaj A.
        • Tymon-Rosario J.
        • Shahi M.
        • Santin A.
        • Klein M.
        • Dolan M.
        • Cimino-Mathews A.
        • Buza N.
        • Ferriss J.S.
        • Stone R.L.
        • Khalifa M.
        • Fader A.N.
        Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study.
        Gynecol. Oncol. 2020; 159 (Epub 2020 Jul 21. PMID: 32709539; PMCID: PMC7541557): 17-22https://doi.org/10.1016/j.ygyno.2020.07.016
        View in Article
        • Jones N.L.
        • Xiu J.
        • Chatterjee-Paer S.
        • Buckley de Meritens A.
        • Burke W.M.
        • Tergas A.I.
        • Wright J.D.
        • Hou J.Y.
        Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas.
        Int. J. Cancer. 2017; 140: 1396-1404https://doi.org/10.1002/ijc.30537
        View in Article
        • Mahdi H.
        • Xiu J.
        • Reddy S.K.
        • Debernardo R.
        Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
        J. Surg. Oncol. 2015; 112: 188-194https://doi.org/10.1002/jso.23993
        View in Article
        • Cuevas D.
        • Valls J.
        • Gatius S.
        • Roman-Canal B.
        • Estaran E.
        • Dorca E.
        • Santacana M.
        • Vaquero M.
        • Eritja N.
        • Velasco A.
        • Matias-Guiu X.
        Targeted Sequencing With a Customized Panel to Assess Histological Typing in Endometrial Carcinoma.
        2020https://doi.org/10.1007/s00428-018-02516-2 (n.d.)
        View in Article
        • Frimer M.
        • Levano K.S.
        • Rodriguez-Gabin A.
        • Wang Y.
        • Goldberg G.L.
        • Horwitz S.B.
        • Hou J.Y.
        Germline mutations of the DNA repair pathways in uterine serous carcinoma.
        Gynecol. Oncol. 2016; 141: 101-107https://doi.org/10.1016/j.ygyno.2015.12.034
        View in Article
        • Ashley C.W.
        • Paula A.D.C.
        • Kumar R.
        • Mandelker D.
        • Pei X.
        • Riaz N.
        • Reis-Filho J.
        • Weigelt B.
        Homologous recombination DNA repair defects in copy-number high serous-like endometrial cancers.
        Gynecol. Oncol. 2019; : 32https://doi.org/10.1016/j.ygyno.2019.04.077
        View in Article
        • Pennington K.P.
        • Walsh T.
        • Lee M.
        • Pennil C.
        • Novetsky A.P.
        • Agnew K.J.
        • Thornton A.
        • Garcia R.
        • Mutch D.
        • King M.C.
        • Goodfellow P.
        • Swisher E.M.
        BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
        Cancer. 2013; 119: 332-338https://doi.org/10.1002/cncr.27720
        View in Article
        • Cocco E.
        • Lopez S.
        • Black J.
        • Bellone S.
        • Bonazzoli E.
        • Predolini F.
        • Ferrari F.
        • Schwab C.L.
        • Menderes G.
        • Zammataro L.
        • Buza N.
        • Hui P.
        • Wong S.
        • Zhao S.
        • Bai Y.
        • Rimm D.L.
        • Ratner E.
        • Litkouhi B.
        • Silasi D.-A.
        • Azodi M.
        • Schwartz P.E.
        • Santin A.D.
        Dual CCNE1/PIK3CA Targeting Is Synergistic in CCNE1-Amplified/PIK3CA-mutated Uterine Serous Carcinomas In Vitro and In Vivo.
        2016https://doi.org/10.1038/bjc.2016.198
        View in Article
        • Boruta D.M.
        • Gehrig P.A.
        • Fader A.N.
        • Olawaiye A.B.
        Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review.
        Gynecol. Oncol. 2009; 115: 142-153https://doi.org/10.1016/j.ygyno.2009.06.011
        View in Article
        • Skaznik-Wikiel M.E.
        • Ueda S.M.
        • Frasure H.E.
        • Rose P.G.
        • Fleury A.
        • Grumbine F.C.
        • Fader A.N.
        Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype?.
        Acta Cytol. 2011; 55: 255-260https://doi.org/10.1159/000324052
        View in Article
        • Huang G.S.
        • Gebb J.S.
        • Einstein M.H.
        • Shahabi S.
        • Novetsky A.P.
        • Goldberg G.L.
        Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors.
        Am. J. Obstet. Gynecol. 2007; 196: 243.e1-243.e5https://doi.org/10.1016/j.ajog.2006.09.035
        View in Article
        • Committee Opinion No A.C.O.G.
        440: the role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding.
        Obstet. Gynecol. 2009; 114: 409-411https://doi.org/10.1097/AOG.0b013e3181b48feb
        View in Article
        • Wang J.
        • Wieslander C.
        • Hansen G.
        • Cass I.
        • Vasilev S.
        • Holschneider C.H.
        Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers.
        Gynecol. Oncol. 2006; 101: 120-125https://doi.org/10.1016/j.ygyno.2005.09.042
        View in Article
        • Lin M.Y.
        • Dobrotwir A.
        • McNally O.
        • Abu-Rustum N.R.
        • Narayan K.
        Role of imaging in the routine management of endometrial cancer.
        Int. J. Gynecol. Obstet. 2018; 143: 109-117https://doi.org/10.1002/ijgo.12618
        View in Article
        • Schmidt M.
        • Segev Y.
        • Sadeh R.
        • Suzan E.
        • Feferkorn I.
        • Kaldawy A.
        • Kligun G.
        • Lavie O.
        Cancer antigen 125 levels are significantly associated with prognostic parameters in uterine papillary serous carcinoma.
        Int. J. Gynecol. Cancer. 2018; 28: 1311-1317https://doi.org/10.1097/IGC.0000000000001300
        View in Article
        • Moore K.N.
        • Fader A. Nickles
        Uterine papillary serous carcinoma.
        Clin. Obstet. Gynecol. 2011; 54: 278-291https://doi.org/10.1097/GRF.0b013e318218c755
        View in Article
        • Boruta D.M.
        • Gehrig P.A.
        • Groben P.A.
        • Bae-Jump V.
        • Boggess J.F.
        • Fowler W.C.
        • Van Le L.
        Uterine serous and grade 3 endometrioid carcinomas.
        Cancer. 2004; 101: 2214-2221https://doi.org/10.1002/cncr.20645
        View in Article
        • Mhawech-Fauceglia P.
        • Herrmann R.F.
        • Kesterson J.
        • Izevbaye I.
        • Lele S.
        • Odunsi K.
        Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.
        Eur. J. Surg. Oncol. 2010; 36: 1195-1201https://doi.org/10.1016/j.ejso.2010.09.010
        View in Article
        • Fader A.N.
        • Java J.
        • Tenney M.
        • Ricci S.
        • Gunderson C.C.
        • Temkin S.M.
        • Spirtos N.
        • Kushnir C.L.
        • Pearl M.L.
        • Zivanovic O.
        • Tewari K.S.
        • O’Malley D.
        • Hartenbach E.M.
        • Hamilton C.A.
        • Gould N.S.
        • Mannel R.S.
        • Rodgers W.
        • Walker J.L.
        Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: an NRG Oncology/Gynecologic Oncology Group ancillary analysis.
        Gynecol. Oncol. 2016; 143: 460-465https://doi.org/10.1016/j.ygyno.2016.10.016
        View in Article
        • Fader A.N.
        • Seamon L.G.
        • Escobar P.F.
        • Frasure H.E.
        • Havrilesky L.A.
        • Zanotti K.M.
        • Secord A.A.
        • Boggess J.F.
        • Cohn D.E.
        • Fowler J.M.
        • Skafianos G.
        • Rossi E.
        • Gehrig P.A.
        Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers.
        Gynecol. Oncol. 2012; 126: 180-185https://doi.org/10.1016/j.ygyno.2012.04.028
        View in Article
        • Gehrig P.A.
        • Van Le L.
        • Fowler W.C.
        The role of omentectomy during the surgical staging of uterine serous carcinoma.
        Int. J. Gynecol. Cancer. 2003; 13: 212-215https://doi.org/10.1136/ijgc-00009577-200303000-00019
        View in Article
        • Todo Y.
        • Kato H.
        • Kaneuchi M.
        • Watari H.
        • Takeda M.
        • Sakuragi N.
        Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis.
        Lancet. 2010; 375: 1165-1172https://doi.org/10.1016/S0140-6736(09)62002-X
        View in Article
        • Basaran D.
        • Bruce S.
        • Aviki E.M.
        • Mueller J.J.
        • Broach V.A.
        • Cadoo K.
        • Soslow R.A.
        • Alektiar K.M.
        • Abu-Rustum N.R.
        • Leitao M.M.
        Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma.
        Gynecol. Oncol. 2020; 156: 70-76https://doi.org/10.1016/j.ygyno.2019.10.005
        View in Article
        • Cusimano M.C.
        • Vicus D.
        • Pulman K.
        • Bernardini M.Q.
        • Laframboise S.
        • May T.
        • Bouchard-Fortier G.
        • Hogen L.
        • Gien L.T.
        • Covens A.L.
        • Kupets R.
        • Clarke B.A.
        • Cesari M.
        • Rouzbahman M.
        • Mirkovic J.
        • Turashvili G.
        • Maganti M.
        • Zia A.
        • Ene G.E.V.
        Sentinel lymph node biopsy versus lymphadenectomy for high-grade endometrial cancer staging (SENTOR trial): a prospective multicenter cohort study.
        in: Soc. Gynecol. Oncol. Annu. Meet. 2020
        View in Article
        • Fader A.N.
        • Drake R.D.
        • O’Malley D.M.
        • Gibbons H.E.
        • Huh W.K.
        • Havrilesky L.J.
        • Gehrig P.A.
        • Tuller E.
        • Axtell A.E.
        • Zanotti K.M.
        Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.
        Cancer. 2009; 115: 2119-2127https://doi.org/10.1002/cncr.24247
        View in Article
        • Fader A.N.
        • Starks D.
        • Gehrig P.A.
        • Secord A.A.
        • Frasure H.E.
        • O’Malley D.M.
        • Tuller E.R.
        • Rose P.G.
        • Havrilesky L.J.
        • Moore K.N.
        • Huh W.K.
        • Axtell A.E.
        • Kelley J.L.
        • Zanotti K.M.
        An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
        Gynecol. Oncol. 2009; 115: 244-248https://doi.org/10.1016/j.ygyno.2009.07.030
        View in Article
        • Moller K.A.
        • Gehrig P.A.
        • Van Le L.
        • Secord A.A.
        • Schorge J.
        The role of optimal debulking in advanced stage serous carcinoma of the uterus.
        Gynecol. Oncol. 2004; 94: 170-174https://doi.org/10.1016/j.ygyno.2004.03.040
        View in Article
        • Thomas M.
        • Mariani A.
        • Cliby W.
        • Keeney G.
        • Podratz K.
        • Dowdy S.
        Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
        Gynecol. Oncol. 2007; 107: 190-193https://doi.org/10.1016/j.ygyno.2007.05.039
        View in Article
        • Mahdi H.
        • Rose P.G.
        • Elshaikh M.A.
        • Munkarah A.
        • Isrow D.
        • Singh S.
        • Waggoner S.
        • Ali-Fehmi R.
        • Morris R.T.
        • Harding J.
        • Debenardo R.
        Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage i non-invasive uterine papillary serous carcinoma. A multi-institutional study.
        Gynecol. Oncol. 2015; 136: 529-533https://doi.org/10.1016/j.ygyno.2014.12.034
        View in Article
        • Mahdi H.
        • Elshaikh M.A.
        • Debenardo R.
        • Munkarah A.
        • Isrow D.
        • Singh S.
        • Waggoner S.
        • Ali-Fehmi R.
        • Morris R.T.
        • Harding J.
        • Moslemi-Kebria M.
        Impact of Adjuvant Chemotherapy and Pelvic Radiation on Pattern of Recurrence and Outcome in Stage I Non-invasive Uterine Papillary Serous Carcinoma. A Multi-institution Study.
        2015https://doi.org/10.1016/j.ygyno.2015.01.544
        View in Article
        • Jenkins Vogel T.
        • Knickerbocker A.
        • Shah C.A.
        • Schiff M.A.
        • Isacson C.
        • Garcia R.L.
        • Goff B.A.
        An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
        J. Gynecol. Oncol. 2015; 26: 25-31https://doi.org/10.3802/jgo.2015.26.1.25
        View in Article
        • Cham S.
        • Huang Y.
        • Tergas A.I.
        • Hou J.Y.
        • Burke W.M.
        • Deutsch I.
        • Ananth C.V.
        • Neugut A.I.
        • Hershman D.L.
        • Wright J.D.
        Utility of radiation therapy for early-stage uterine papillary serous carcinoma.
        Gynecol. Oncol. 2017; 145: 269-276https://doi.org/10.1016/j.ygyno.2017.03.003
        View in Article
        • Fader A.N.
        • Nagel C.
        • Axtell A.E.
        • Zanotti K.M.
        • Kelley J.L.
        • Moore K.N.
        • Secord A.A.
        • Walsh C.S.
        • Huh W.K.
        • Gehrig P.A.
        • Gibbons H.
        • Rose P.G.
        • Havrilesky L.J.
        • Tuller E.
        • Drake R.D.
        • Bottsford-Miller J.
        • O’Malley D.M.
        Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
        Gynecol. Oncol. 2009; 112: 558-562https://doi.org/10.1016/j.ygyno.2008.11.016
        View in Article
        • Kelly M.G.
        • O’malley D.M.
        • Hui P.
        • Mcalpine J.
        • Yu H.
        • Rutherford T.J.
        • Azodi M.
        • Schwartz P.E.
        Improved Survival in Surgical Stage I Patients With Uterine Papillary Serous Carcinoma (UPSC) Treated With Adjuvant Platinum-based Chemotherapy.
        2005https://doi.org/10.1016/j.ygyno.2005.06.012
        View in Article
        • Fader A.N.
        • Boruta D.
        • Olawaiye A.B.
        • Gehrig P.A.
        Uterine papillary serous carcinoma: epidemiology, pathogenesis and management.
        Curr. Opin. Obstet. Gynecol. 2010; 22: 21-29https://doi.org/10.1097/GCO.0b013e328334d8a3
        View in Article
        • McMillian N. Nicole
        • Scavone M. Jillian
        • Fisher C.M.
        • Frederick P.
        • Gaffney D.K.
        • George S.
        • Han E.
        • Huh W.K.
        • Lurain J.R.
        • Lurie H. Robert
        • Mariani A.
        • Mutch D.
        • Nagel C.
        • Yashar C.M.
        • Chair V.
        • Bean S.
        • Bradley K.
        • Campos S.M.
        • Chon H. Sook
        • Chu C.
        • Cohn D.
        • Crispens M. Ann
        • Damast S.
        • Dorigo O.
        • Eifel P.J.
        • Nekhlyudov L.
        • Fader A. Nickles
        • Remmenga S.W.
        • Fred
        • P.R. Buffett Cancer Center Kevin Reynolds
        • Tillmanns R. Sisodia T.
        • St Jude
        • Ueda S.
        • Urban R.
        NCCN Guidelines Version 4.2019 Uterine Neoplasms.
        https://www.nccn.org/professionals/physician_gls/PDF/cervical.pdf
        Date: 2019
        (accessed November 13, 2019)
        View in Article
        • Hui P.
        • Kelly M.
        • O’Malley D.M.
        • Tavassoli F.
        • Schwartz P.E.
        Minimal uterine serous carcinoma: a clinicopathological study of 40 cases.
        Mod. Pathol. 2005; 18: 75-82https://doi.org/10.1038/modpathol.3800271
        View in Article
        • Semaan A.
        • Mert I.
        • Munkarah A.R.
        • Bandyopadhyay S.
        • Mahdi H.S.
        • Winer I.S.
        • Nucci M.R.
        • Hussein Y.
        • Quershi F.
        • Hayek K.
        • Tabassum F.
        • Alosh B.
        • Schultz D.S.
        • Cote M.L.
        • Van De Vijver K.K.
        • Morris R.T.
        • Oliva E.
        • Ali-Fehmi R.
        Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study.
        Int. J. Gynecol. Pathol. 2013; 32: 181-187https://doi.org/10.1097/PGP.0b013e318273fc55
        View in Article
        • Farrell R.
        • Scurry J.
        • Otton G.
        • Hacker N.F.
        Clinicopathologic Review of Malignant Polyps in Stage 1A Carcinoma of the Endometrium.
        2005https://doi.org/10.1016/j.ygyno.2005.03.044
        View in Article
        • Chang-Halpenny C.N.
        • Natarajan S.
        • Hwang-Graziano J.
        Early Stage Papillary Serous or Clear Cell Carcinoma Confined to or Involving an Endometrial Polyp: Outcomes With and Without Adjuvant Therapy.
        2013https://doi.org/10.1016/j.ygyno.2013.10.010
        View in Article
        • Viswanathan A.N.
        • Macklin E.A.
        • Berkowitz R.
        • Matulonis U.
        The Importance of Chemotherapy and Radiation in Uterine Papillary Serous Carcinoma.
        2011https://doi.org/10.1016/j.ygyno.2011.09.005
        View in Article
        • Tortorella L.
        • Langstraat C.L.
        • Weaver A.L.
        • McGree M.E.
        • Bakkum-Gamez J.N.
        • Dowdy S.C.
        • Cliby W.A.
        • Keeney G.L.
        • Sherman M.E.
        • Weroha S.J.
        • Mariani A.
        • Podratz K.C.
        Uterine serous carcinoma: reassessing effectiveness of platinum-based adjuvant therapy.
        Gynecol. Oncol. 2018; 149: 291-296https://doi.org/10.1016/j.ygyno.2018.02.022
        View in Article
        • Hogberg T.
        • Signorelli M.
        • De Oliveira C.F.
        • Fossati R.
        • Lissoni A.A.
        • Sorbe B.
        • Andersson H.
        • Grenman S.
        • Lundgren C.
        • Rosenberg P.
        • Boman K.
        • Tholander B.
        • Scambia G.
        • Reed N.
        • Cormio G.
        • Tognon G.
        • Clarke J.
        • Sawicki T.
        • Zola P.
        • Kristensen G.
        Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies.
        Eur. J. Cancer. 2010; 46: 2422-2431https://doi.org/10.1016/j.ejca.2010.06.002
        View in Article
        • Randall M.E.
        • Filiaci V.
        • Scott D.
        • Von Gruenigen V.
        • Huang H.
        • Yashar C.M.
        • Robert S. Mannel
        • Kim J.-W.
        • Salani R.
        • Disilvestro P.A.
        • Burke J.J.
        • Rutherford T.
        • Nick M. Spirtos
        • Terada Keith
        • Penny R. Anderson
        • Brewster W.R.
        • Small W.
        • Aghajanian C.A.
        • Miller D.S.
        Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/ carboplatin in high-intermediate and high-risk early-stage endometrial cancer.
        J. Clin. Oncol. 2019; 37: 1810-1818https://doi.org/10.1200/JCO.18
        View in Article
        • Randall M.E.
        • Filiaci V.L.
        • Muss H.
        • Spirtos N.M.
        • Mannel R.S.
        • Fowler J.
        • Thigpen J.T.
        • Benda J.A.
        Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study.
        J. Clin. Oncol. 2006; 24: 36-44https://doi.org/10.1200/JCO.2004.00.7617
        View in Article
        • de Boer S.M.
        • Powell M.E.
        • Mileshkin L.
        • Katsaros D.
        • Bessette P.
        • Haie-Meder C.
        • Ottevanger P.B.
        • Ledermann J.A.
        • Khaw P.
        • Colombo A.
        • Fyles A.
        • Baron M.H.
        • Jürgenliemk-Schulz I.M.
        • Kitchener H.C.
        • Nijman H.W.
        • Wilson G.
        • Brooks S.
        • Carinelli S.
        • Provencher D.
        • Hanzen C.
        • Lutgens L.C.H.W.
        • Smit V.T.H.B.M.
        • Singh N.
        • Do V.
        • D’Amico R.
        • Nout R.A.
        • Feeney A.
        • Verhoeven-Adema K.W.
        • Putter H.
        • Creutzberg C.L.
        • McCormack M.
        • Whitmarsh K.
        • Allerton R.
        • Gregory D.
        • Symonds P.
        • Hoskin P.J.
        • Adusumalli M.
        • Anand A.
        • Wade R.
        • Stewart A.
        • Taylor W.
        • Kruitwagen R.F.P.M.
        • Hollema H.
        • Pras E.
        • Snyers A.
        • Stalpers L.
        • Jobsen J.J.
        • Slot A.
        • Mens J.W.M.
        • Stam T.C.
        • Van Triest B.
        • Van der Steen-Banasik E.M.
        • De Winter K.A.J.
        • Quinn M.A.
        • Kolodziej I.
        • Pyman J.
        • Johnson C.
        • Capp A.
        • Fossati R.
        • Gribaudo S.
        • Lissoni A.A.
        • Ferrero A.
        • Artioli G.
        • Davidson C.
        • McLachlin C.M.
        • Ghatage P.
        • Rittenberg P.V.C.
        • Souhami L.
        • Thomas G.
        • Duvillard P.
        • Berton-Rigaud D.
        • Tubiana-Mathieu N.
        Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
        Lancet Oncol. 2018; 19: 295-309https://doi.org/10.1016/S1470-2045(18)30079-2
        View in Article
        • de Boer S.M.
        • Powell M.E.
        • Mileshkin L.
        • Katsaros D.
        • Bessette P.
        • Haie-Meder C.
        • Ottevanger P.B.
        • Ledermann J.A.
        • Khaw P.
        • D’Amico R.
        • Fyles A.
        • Baron M.-H.
        • Jürgenliemk-Schulz I.M.
        • Kitchener H.C.
        • Nijman H.W.
        • Wilson G.
        • Brooks S.
        • Gribaudo S.
        • Provencher D.
        • Hanzen C.
        • Kruitwagen R.F.
        • Smit V.T.H.B.M.
        • Singh N.
        • Do V.
        • Lissoni A.
        • Nout R.A.
        • Feeney A.
        • Verhoeven-Adema K.W.
        • Putter H.
        • Creutzberg C.L.
        • McCormack M.
        • Whitmarsh K.
        • Allerton R.
        • Gregory D.
        • Symonds P.
        • Hoskin P.
        • Adusumalli M.
        • Anand A.
        • Wade R.
        • Stewart A.
        • Taylor W.
        • Lutgens L.
        • Hollema H.
        • Pras E.
        • Snyers A.
        • Westerveld G.
        • Jobsen J.
        • Slot A.
        • Mens J.
        • Stam T.
        • Van Triest B.
        • Van der Steen-Banasik E.
        • De Winter K.
        • Quinn M.
        • Kolodziej I.
        • Pyman J.
        • Johnson C.
        • Capp A.
        • Fossati R.
        • Colombo A.
        • Carinelli S.
        • Ferrero A.
        • Artioli G.
        • Davidson C.
        • McLachlin C.
        • Ghatage P.
        • Rittenberg P.
        • Souhami L.
        • Thomas G.
        • Duvillard P.
        • Berton-Rigaud D.
        • Tubiana-Mathieu N.
        Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
        Lancet Oncol. 2019; 20: 1273-1285https://doi.org/10.1016/s1470-2045(19)30395-x
        View in Article
        • Matei D.
        • Filiaci V.
        • Randall M.E.
        • Mutch D.
        • Steinhoff M.M.
        • DiSilvestro P.A.
        • Moxley K.M.
        • Kim Y.M.
        • Powell M.A.
        • O’Malley D.M.
        • Spirtos N.M.
        • Small W.
        • Tewari K.S.
        • Richards W.E.
        • Nakayama J.
        • Matulonis U.A.
        • Huang H.Q.
        • Miller D.S.
        Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer.
        N. Engl. J. Med. 2019; 380: 2317-2326https://doi.org/10.1056/NEJMoa1813181
        View in Article
        • Lester-Coll N.H.
        • Park H.S.
        • Rutter C.E.
        • Corso C.D.
        • Young M.R.
        • Ratner E.S.
        • Litkouhi B.
        • Decker R.H.
        • Yu J.B.
        • Damast S.
        Who Benefits from Chemoradiation in Stage III-IVA Endometrial Cancer? An analysis of the National Cancer Data Base.
        2016https://doi.org/10.1016/j.ygyno.2016.04.544
        View in Article
        • Xiang M.
        • English D.P.
        • Kidd E.A.
        Defining the Survival Benefit of Adjuvant Pelvic Radiotherapy and Chemotherapy Versus Chemotherapy Alone in Stages III-IVA Endometrial Carcinoma.
        2019https://doi.org/10.1016/j.ygyno.2019.06.020
        View in Article
        • Mahdi H.
        • Nutter B.
        • Abdul-Karim F.
        • Amarnath S.
        • Rose P.G.
        The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone.
        J. Gynecol. Oncol. 2016; 27https://doi.org/10.3802/jgo.2016.27.e19
        View in Article
        • Menderes G.
        • Bonazzoli E.
        • Bellone S.
        • Altwerger G.
        • Black J.D.
        • Dugan K.
        • Pettinella F.
        • Masserdotti A.
        • Riccio F.
        • Bianchi A.
        • Zammataro L.
        • de Haydu C.
        • Buza N.
        • Hui P.
        • Wong S.
        • Huang G.S.
        • Litkouhi B.
        • Ratner E.
        • Silasi D.A.
        • Azodi M.
        • Schwartz P.E.
        • Santin A.D.
        Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
        Gynecol. Oncol. 2017; 147: 145-152https://doi.org/10.1016/j.ygyno.2017.07.009
        View in Article
        • Black J.
        • Menderes G.
        • Bellone S.
        • Schwab C.L.
        • Bonazzoli E.
        • Ferrari F.
        • Predolini F.
        • De Haydu C.
        • Cocco E.
        • Buza N.
        • Hui P.
        • Wong S.
        • Lopez S.
        • Ratner E.
        • Silasi D.-A.
        • Azodi M.
        • Litkouhi B.
        • Schwartz P.E.
        • Goedings P.
        • Beusker P.H.
        • Van Der Lee M.M.C.
        • Timmers C.M.
        • Dokter W.H.A.
        • Santin A.D.
        SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine serous carcinoma with HER2/Neu expression.
        Mol. Cancer Ther. 2016; 15https://doi.org/10.1158/1535-7163.MCT-16-0163
        View in Article
        • Lopez S.
        • Cocco E.
        • Black J.
        • Bellone S.
        • Bonazzoli E.
        • Predolini F.
        • Ferrari F.
        • Schwab C.L.
        • English D.P.
        • Ratner E.
        • Silasi D.A.
        • Azodi M.
        • Schwartz P.E.
        • Terranova C.
        • Angioli R.
        • Santin A.D.
        Dual HER2/PIK3CA targeting overcomes single-agent acquired resistance in HER2-amplified uterine serous carcinoma cell lines in vitro and in vivo.
        Mol. Cancer Ther. 2015; 14: 2519-2526https://doi.org/10.1158/1535-7163.MCT-15-0383
        View in Article
        • Schwab C.L.
        • Bellone S.
        • English D.P.
        • Roque D.M.
        • Lopez S.
        • Cocco E.
        • Nicoletti R.
        • Bortolomai I.
        • Bonazzoli E.
        • Ratner E.
        • Silasi D.A.
        • Azodi M.
        • Schwartz P.E.
        • Rutherford T.J.
        • Santin A.D.
        Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
        Br. J. Cancer. 2014; 111: 1750-1756https://doi.org/10.1038/bjc.2014.519
        View in Article
        • Fleming G.F.
        • Sill M.W.
        • Darcy K.M.
        • McMeekin D.S.
        • Thigpen J.T.
        • Adler L.M.
        • Berek J.S.
        • Chapman J.A.
        • DiSilvestro P.A.
        • Horowitz I.R.
        • Fiorica J.V.
        Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study.
        Gynecol. Oncol. 2010; 116: 15-20https://doi.org/10.1016/j.ygyno.2009.09.025
        View in Article
        • Pelligra S.
        • Buza N.
        • Hui P.
        • Bellone S.
        • Zeybek B.
        • Ratner E.
        • Schwartz P.E.
        • Scambia G.
        • Santin A.D
        Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma.
        Gynecol Oncol Rep. 2020; 32 (PMID: 32140533; PMCID: PMC7049633): 100554https://doi.org/10.1016/j.gore.2020.100554
        View in Article
        • Menderes G.
        • Lopez S.
        • Han C.
        • Altwerger G.
        • Gysler S.
        • Varughese J.
        • Schwartz P.E.
        • Santin A.D.
        Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it.
        Discov. Med. 2018; 26 (accessed November 10, 2019): 39-50
        http://www.discoverymedicine.com/Gulden-Menderes/2018/08/mechanisms-of-resistance-to-her2-targeted-therapies-in-uterine-serous-carcinoma/
        View in Article
        • Fader A.N.
        • Roque D.M.
        • Siegel E.
        • Buza N.
        • Hui P.
        • Abdelghany O.
        • Chambers S.K.
        • Secord A. Alvarez
        • Havrilesky L.
        • Backes F.
        • Nevadunsky N.
        • Edraki B.
        • Pikaart D.
        • Lowery W.
        • ElSahwi K.S.
        • Celano P.
        • Bellone S.
        • Azodi M.
        • Litkouhi B.
        • Ratner E.
        • Silasi D.-A.
        • Schwartz P.E.
        • Santin A.D.
        Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu.
        J Clin Oncol. 2018; 36 (doi:10.1200/JCO): 2044-2051
        View in Article
        • Fader A.N.
        • Roque D.M.
        • Siegel E.
        • Buza N.
        • Hui P.
        • Abdelghany O.
        • Chambers S.
        • Secord A.A.
        • Havrilesky L.
        • Malley D.M.
        • Backes F.J.
        • Nevadunsky N.
        • Edraki B.
        • Pikaart D.
        • Lowery W.
        • ElSahwi K.
        • Celano P.
        • Bellone S.
        • Azodi M.
        • Litkouhi B.
        • Ratner E.
        • Silasi D.-A.
        • Schwartz P.E.
        • Santin A.D.
        Randomized phase II trial of carboplatin–paclitaxel compared with carboplatin–paclitaxel–trastuzumab in advanced (Stage III–IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis.
        Clin. Cancer Res. 2020; https://doi.org/10.1158/1078-0432.CCR-20-0953
        View in Article
        • Ott P.A.
        • Bang Y.-J.
        • Berton-Rigaud D.
        • Elez E.
        • Pishvaian M.J.
        • Rugo H.S.
        • Puzanov I.
        • Mehnert J.M.
        • Aung K.L.
        • Lopez J.
        • Carrigan M.
        • Saraf S.
        • Chen M.
        • Soria J.-C.
        Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
        2017https://doi.org/10.1200/JCO
        View in Article
        • Konstantinopoulos P.A.
        • Luo W.
        • Liu J.F.
        • Doga C. Gulhan
        • Krasner C.
        • Ishizuka J.J.
        • Gockley A.A.
        • Buss M.
        • Whitfield B. Growdon
        • Crowe Heather
        • Campos S.
        • Lindeman N.I.
        • Hill S.
        • Stover E.
        • Schumer S.
        • Wright A.A.
        • Curtis J.
        • Quinn R.
        • Whalen C.
        • Gray K.P.
        • Penson R.T.
        • Cannistra S.A.
        • Gini
        • Fleming F.
        • Matulonis U.A.
        Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer.
        J. Clin. Oncol. 2019; 37: 2786-2794https://doi.org/10.1200/JCO.19
        View in Article
        • Oaknin A.
        • Duska L.R.
        • Sullivan R.J.
        • Pothuri B.
        • Ellard S.L.
        • Leath C.A.
        • Moreno V.
        • Kristeleit R.S.
        • Guo W.
        • Danaee H.
        • Im E.
        • Gilbert L.
        Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer.
        Gynecol. Oncol. 2019; 154: 17https://doi.org/10.1016/j.ygyno.2019.04.044
        View in Article
        • Makker V.
        • Rasco D.
        • Vogelzang N.J.
        • Brose M.S.
        • Cohn A.L.
        • Mier J.
        • Di Simone C.
        • Hyman D.M.
        • Stepan D.E.
        • Dutcus C.E.
        • Schmidt E.V.
        • Guo M.
        • Sachdev P.
        • Shumaker R.
        • Aghajanian C.
        • Taylor M.
        Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
        Lancet Oncol. 2019; https://doi.org/10.1016/S1470-2045(19)30020-8
        View in Article
        • Yang X.
        • Leslie G.
        • Doroszuk A.
        • Schneider S.
        • Allen J.
        • Decker B.
        • Dunning A.M.
        • Redman J.
        • Scarth J.
        • Plaskocinska I.
        • Luccarini C.
        • Shah M.
        • Pooley K.
        • Dorling L.
        • Lee A.
        • Adank M.A.
        • Adlard J.
        • AittomäkiAittom K.
        • Andrulis I.L.
        • Ang P.
        • Barwell J.
        • Bernstein J.L.
        • Bobolis K.
        • Borg A.
        • Blomqvist C.
        • Claes K.B.
        • Concannon P.
        • Cuggia A.
        • Culver J.O.
        • Damiola F.
        • de Pauw A.
        • Diez O.
        • Dolinsky J.S.
        • Domchek S.M.
        • Engel C.
        • Evans D. Gareth
        • Fostira F.
        • Garber J.
        • Golmard L.
        • Goode E.L.
        • Gruber S.B.
        • Hahnen E.
        • Hake C.
        • Heikkinen T.
        • Hurley J.E.
        • Janavicius R.
        • Kleibl Z.
        • Kleiblova P.
        • Konstantopoulou I.
        • Kvist A.
        • Laduca H.
        • Lee A.S.
        • Lesueur F.
        • Maher E.R.
        • Mannermaa A.
        • Manoukian S.
        • McFarland R.
        • McKinnon W.
        • Meindl A.
        • Metcalfe K.
        • Taib N. Aishah Mohd
        • Moilanen J.
        • Nathanson K.L.
        • Neuhausen S.
        • Ng P. Sze
        • Nguyen-Dumont T.
        • Nielsen S.M.
        • Obermair F.
        • Offit K.
        • Olopade O.I.
        • Ottini L.
        • Penkert J.
        • PylkäsPylk K.
        • Radice P.
        • Ramus S.J.
        • Rudaitis V.
        • Side L.
        • Silva-Smith R.
        • Silvestri V.
        • Skytte A.-B.
        • Slavin T.
        • Soukupova J.
        • Tondini C.
        • Trainer A.H.
        • Unzeitig G.
        • Usha L.
        • van Overeem Hansen T.
        • Whitworth J.
        • Wood M.
        • Yip C. Har
        • Yoon S.-Y.
        • Yussuf A.
        • Zogopoulos G.
        • Goldgar D.
        • Hopper J.L.
        • Chenevix-Trench G.
        • Pharoah P.
        • George S.H.
        • Balmaña J.
        • Houdayer C.
        • James P.
        • El-Haffaf Z.
        • Ehrencrona H.
        • Janatova M.
        • Peterlongo P.
        • Nevanlinna H.
        • Schmutzler R.
        • Teo S.-H.
        • Robson M.
        • Pal T.
        • Couch F.
        • Weitzel J.N.
        • Elliott A.
        • Southey M.
        • Winqvist R.
        • Easton D.F.
        • Foulkes W.D.
        • Antoniou A.C.
        • Tischkowitz M.
        Downloaded from ascopubs.org by Institute of Oncology Ljubljana on, J Clin Oncol.
        38. 2020: 674-685https://doi.org/10.1200/JCO.19
        View in Article
        • Li B.T.
        • Makker V.
        • Buonocore D.J.
        • Offin M.D.
        • Olah Z.T.
        • Panora E.
        • Shen R.
        • Ho A.L.
        • Yaeger R.
        • Iyer G.
        • Ginsberg M.S.
        • Ulaner G.
        • Solit D.B.
        • Hyman D.M.
        • Rudin C.M.
        • Berger M.F.
        • Baselga J.
        • Scaltriti M.
        • Arcila M.E.
        • Kris M.G.
        A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
        J. Clin. Oncol. 2018; 36: 2502https://doi.org/10.1200/jco.2018.36.15_suppl.2502
        View in Article
        • Jhaveri K.L.
        • Wang X.V.
        • Makker V.
        • Luoh S.-W.
        • Mitchell E.P.
        • Zwiebel J.A.
        • Sharon E.
        • Gray R.J.
        • Li S.
        • McShane L.M.
        • Rubinstein L.V.
        • Patton D.
        • Williams P.M.
        • Hamilton S.R.
        • Conley B.A.
        • Arteaga C.L.
        • Harris L.N.
        • O’Dwyer P.J.
        • Chen A.P.
        • Flaherty K.T.
        Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH Trial (EAY131) Sub-protocol Q.
        Ann. Oncol. 2019; https://doi.org/10.1093/annonc/mdz291
        View in Article
        • Banerji U.
        • van Herpen C.M.L.
        • Saura C.
        • Thistlethwaite F.
        • Lord S.
        • Moreno V.
        • Macpherson I.R.
        • Boni V.
        • Rolfo C.
        • de Vries E.G.E.
        • Rottey S.
        • Geenen J.
        • Eskens F.
        • Gil-Martin M.
        • Mommers E.C.
        • Koper N.P.
        • Aftimos P.
        Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
        Lancet Oncol. 2019; 20: 1124-1135https://doi.org/10.1016/S1470-2045(19)30328-6
        View in Article
        • El-Sahwi K.
        • Bellone S.
        • Cocco E.
        • Cargnelutti M.
        • Casagrande F.
        • Bellone M.
        • Abu-Khalaf M.
        • Buza N.
        • Tavassoli F.A.
        • Hui P.
        • Silasi D.A.
        • Azodi M.
        • Schwartz P.E.
        • Rutherford T.J.
        • Pecorelli S.
        • Santin A.D.
        In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
        Br. J. Cancer. 2010; 102: 134-143https://doi.org/10.1038/sj.bjc.6605448
        View in Article
        • English D.P.
        • Roque D.M.
        • Carrara L.
        • Lopez S.
        • Bellone S.
        • Cocco E.
        • Bortolomai I.
        • Schwartz P.E.
        • Rutherford T.
        • Santin A.D.
        HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
        Gynecol. Oncol. 2013; 131: 753-758https://doi.org/10.1016/j.ygyno.2013.08.033
        View in Article
        • Lopez S.
        • Schwab C.L.
        • Cocco E.
        • Bellone S.
        • Bonazzoli E.
        • English D.P.
        • Schwartz P.E.
        • Rutherford T.
        • Angioli R.
        • Santin A.D.
        Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
        Gynecol. Oncol. 2014; 135: 312-317https://doi.org/10.1016/j.ygyno.2014.08.024
        View in Article
        • Ray-Coquard I.
        • Favier L.
        • Weber B.
        • Roemer-Becuwe C.
        • Bougnoux P.
        • Fabbro M.
        • Floquet A.
        • Joly F.
        • Plantade A.
        • Paraiso D.
        • Pujade-Lauraine E.
        Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.
        Br. J. Cancer. 2013; 108https://doi.org/10.1038/bjc.2013.183
        View in Article
        • Slomovitz B.M.
        • Jiang Y.
        • Yates M.S.
        • Soliman P.T.
        • Johnston T.
        • Nowakowski M.
        • Levenback C.
        • Zhang Q.
        • Ring K.
        • Munsell M.F.
        • Gershenson D.M.
        • Lu K.H.
        • Coleman R.L.
        Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
        J. Clin. Oncol. 2015; 33: 930-936https://doi.org/10.1200/JCO.2014.58.3401
        View in Article
        • Colombo N.
        • McMeekin D.S.
        • Schwartz P.E.
        • Sessa C.
        • Gehrig P.A.
        • Holloway R.
        • Braly P.
        • Matei D.
        • Morosky A.
        • Dodion P.F.
        • Einstein M.H.
        • Haluska F.
        Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.
        Br. J. Cancer. 2013; 108: 1021-1026https://doi.org/10.1038/bjc.2013.59
        View in Article
        • Santin A.D.
        • Filiaci V.
        • Bellone S.
        • Ratner E.S.
        • Mathews C.A.
        • Cantuaria G.
        • Gunderson C.C.
        • Rutledge T.
        • Buttin B.M.
        • Lankes H.A.
        • Frumovitz M.
        • Khleif S.N.
        • Huh W.K.
        • Birrer M.J.
        Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: an NRG Oncology study (NRG-GY008).
        Gynecol. Oncol. Rep. 2020; 31https://doi.org/10.1016/j.gore.2019.100532
        View in Article
        • De Jonge M.M.
        • Auguste A.
        • Van Wijk L.M.
        • Schouten P.C.
        • Meijers M.
        • Ter Haar N.T.
        • Smit V.T.H.B.M.
        • Nout R.A.
        • Glaire M.A.
        • Church D.N.
        • Vrieling H.
        • Job B.
        • Boursin Y.
        • De Kroon C.D.
        • Rouleau E.
        • Leary A.
        • Vreeswijk M.P.
        • Bosse T.
        Frequent homologous recombination deficiency in high-grade endometrial carcinomas.
        Clin. Cancer Res. 2019; 25: 1087-1097https://doi.org/10.1158/1078-0432.CCR-18-1443
        View in Article
        • Liu J.F.
        • Tayob N.
        • Campos S.M.
        • Wright A.A.
        • Krasner C.
        • Schumer S.
        • Horowitz N.S.
        • Veneris J.T.
        • Xiong N.
        • West G.
        • Quinn R.
        • Matulonis U.A.
        • Konstantinopoulos P.A.
        A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma [abstract].
        in: Soc. Gynecol. Oncol. Annu. Meet. 2020
        View in Article

      Article info

      Publication history

      Published online: November 04, 2020
      Accepted: October 14, 2020
      Received: July 29, 2020

      Identification

      DOI: https://doi.org/10.1016/j.ygyno.2020.10.017

      Copyright

      © 2020 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX